Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
Global Leadership<br />
People around the world<br />
entrust to <strong>Bausch</strong> & <strong>Lomb</strong><br />
their most precious sense –<br />
the sense of sight. To be<br />
worthy of that trust, we<br />
constantly strive to find<br />
a better way in all that we<br />
do. By offering the most<br />
comprehensive and innovative<br />
line of eye care products,<br />
and through our partnerships<br />
with eye care professionals,<br />
our goal is to enhance the<br />
visual performance of people<br />
of all ages. Said another<br />
way, our vision is to be<br />
Number One in the Eyes<br />
of the World.<br />
In the surgical business, we continue to be excited by the rapid growth<br />
of refractive surgery. We are already the global leader in this area, offering<br />
the most advanced technology covering all aspects of LASIK, the most<br />
common refractive procedure. We are currently conducting clinical trials<br />
in Europe to integrate our unique diagnostic and refractive technologies.<br />
This will enable surgeons to determine an individualized customized<br />
ablative pattern for treating each patient, and thus allow patients to<br />
attain vision better than 20/20 – in essence, perfect vision. In turn,<br />
it has the potential to provide <strong>Bausch</strong> & <strong>Lomb</strong> with an annuity stream of<br />
revenues to augment our equipment sales and capitalize on the projected<br />
growth in global refractive surgery procedures. We will also maintain a<br />
strong presence in cataract surgery, the most common ophthalmic<br />
surgical procedure today, where<br />
“Number one in<br />
we expect to introduce technology<br />
that will allow for less invasive surgery and new<br />
intraocular lens offerings over the next few years.<br />
In our pharmaceuticals business, our expanded R&D<br />
efforts are yielding the breakthrough technology that we<br />
believe can provide future breakout potential for <strong>Bausch</strong> &<br />
<strong>Lomb</strong>. In 2000, we will be in Phase III clinical trials for an<br />
extension to the Lotemax line with a product designed to<br />
treat eye inflammation and infection, with an expected<br />
launch in 2001. However, our most exciting opportunity is<br />
with a drug delivery technology to treat sight-threatening<br />
See the future 6<br />
<strong>Bausch</strong> & <strong>Lomb</strong><br />
the eyes of the world”
Change language